Protocol Ledger

NCT04993755 · Phase II · COMPLETED

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Interventional Phase II clinical trial protocol NCT04993755 sponsored by Transposon Therapeutics in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-01 Enrollment: 42 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04993755
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04993755
Protocol FieldVerified Registry Value
NCT IdentifierNCT04993755
Consolidated Lead SponsorTransposon Therapeutics
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment42 participants (ACTUAL)
Registered Start Date2021-10-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI